Compare National Beverage Corp. (FIZZ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Vertex Pharmaceuticals Incorporated — how do they compare? National Beverage Corp. trades at $30.39 (market cap $2.89B), while Vertex Pharmaceuticals Incorporated trades at $508.94 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 44.1× National Beverage Corp.'s market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 33 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| FIZZ | VRTX | |
|---|---|---|
Market Cap | $2.89B | $127.55B |
Volume | 553,950 | 1,487,944 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $557.96 |
52-Week Low | $29.20 | $407.37 |
Typical Hold Time | 33 Days | 120 Days |
Enterprise Value | $2.84B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $30.58, up 3.31% today, but faces bearish technical signals with recent earnings misses. Revenue has stagnated around $1.2B annually, though net income margins improved to 15.55% in 2025. The company maintains strong profitability with 40.13% ROE but faces margin pressure from input costs. A $3.25 special dividend payment in July 2026 reduced shareholder equity significantly.
Outlook remains challenging with analyst consensus leaning bearish (50% sell ratings). While valuation appears reasonable (P/E 16.58), stagnant growth and consecutive earnings misses pose headwinds. The key opportunity lies in potential revenue recovery, but investors face risks from competitive pressures and ongoing margin compression.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
